Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2002-01-25
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.3s-guojian.com
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2021-12-06
- Target Recruit Count
- 162
- Registration Number
- NCT05145179
A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2021-11-30
- Target Recruit Count
- 70
- Registration Number
- NCT05138146
- Locations
- 🇨🇳
Beijing ji shui tan Hospital, Beijing, Beijing, China
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2021-08-30
- Target Recruit Count
- 34
- Registration Number
- NCT05027373
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-06-10
- Target Recruit Count
- 60
- Registration Number
- NCT04922151
- Locations
- 🇨🇳
Peking Union Medical College Hospital, BeiJing, China
601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2020-12-16
- Target Recruit Count
- 60
- Registration Number
- NCT04667910
- Locations
- 🇨🇳
TianJing Medical University Eye Hospital, TianJing, TianJing, China
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2020-12-16
- Target Recruit Count
- 60
- Registration Number
- NCT04667897
- Locations
- 🇨🇳
BeiJing Hospital, BeiJing, Beijing, China
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2022-11-10
- Target Recruit Count
- 40
- Registration Number
- NCT04527718
- Locations
- 🇺🇸
Covance Dallas Clinical Research Unit, Dallas, Texas, United States
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2020-07-13
- Target Recruit Count
- 67
- Registration Number
- NCT04468997
- Locations
- 🇨🇳
BeiJing Hospital, Beijing, China
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2021-08-23
- Target Recruit Count
- 75
- Registration Number
- NCT04466254
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-01-28
- Target Recruit Count
- 52
- Registration Number
- NCT04445038
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath